MENLO PARK, Calif., Dec. 12, 2011 /PRNewswire/ -- BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced that Michael Kleine, President & Chief Executive Officer of EndoGastric Solutions, Inc. has joined its Board of Directors.
"Mr. Kleine's impressive leadership experience in the field will accelerate the commercialization of our novel biologic cardiovascular therapies. We are delighted to have him as part of the team," said Allan Mishra, MD, Founder of BioParadox.
Mr. Kleine has more than 25 years of experience in the medical device and healthcare industries. He has successfully managed several global biomedical companies focused on the market advancement of numerous leading-edge products through commercialization strategies and operational excellence.
Previously, Mr. Kleine has served as President & Chief Executive Officer of Biosensors. After major restructuring of the Company, he achieved record revenue and market share gains by focusing on markets in Asia/Pacific, China and Europe. Under his leadership, the market cap of Biosensors grew from $187 million to $662 million. Prior to that, he served as President and Chief Executive Officer of Microvention Inc., a leading developer, manufacturer and marketer of minimally invasive products for treatment of cerebral and peripheral vascular disease. During his tenure at Microvention, Mr. Kleine successfully grew the company until it was acquired by Terumo Corporation (Japan).
Mr. Kleine also served as Chief Executive Officer of Thermo Cardiosystems Inc., an $80 million manufacturer and distributor of left ventricular assist systems, incision and blood coagulation devices, until its acquisition by Thoratec. He was also the former President and Chief Executive Officer of Sorin Biomedical Inc., a $54 million manufacturer and distributor of cardiopulmonary equipment that successfully merged with Cobe, Inc. and President of Bird Medical Technologies, a $64 million manufacturer and distributor of ventilators and disposable respirator and infection control products.
BioParadox is innovating the use of Platelet Cell Therapy (PCT) for the treatment of cardiovascular disease. The company's first products, VitaKine® and RevaTen® are proprietary formulations that have been shown to enhance cardiovascular function. They are produced exclusively by BioParadox.
Copyright©2010 PR Newswire.
All rights reserved